AI Engines For more Details: Perplexity Kagi Labs You
Muscle Relaxation: Zoxazolamine acts as a muscle relaxant by interfering with neuromuscular transmission and blocking the conduction of nerve impulses to skeletal muscles. It acts as a centrally acting muscle relaxant, meaning it exerts its effects on the central nervous system rather than directly on skeletal muscle tissue.
Experimental Models: Zoxazolamine is commonly used in experimental models to study the effects of muscle relaxation and to investigate neuromuscular function. It is often administered to laboratory animals to induce muscle paralysis or relaxation for research purposes, particularly in studies related to neuromuscular disorders, muscle physiology, and drug development.
Neuromuscular Junction: Zoxazolamine acts by inhibiting the release of acetylcholine at the neuromuscular junction, the site where nerve impulses are transmitted to muscle fibers. By blocking neuromuscular transmission, zoxazolamine causes temporary muscle paralysis or relaxation, which can be useful for studying neuromuscular function and assessing the effects of drugs that target the neuromuscular junction.
Clinical Applications: While zoxazolamine itself is not used clinically as a therapeutic agent, its pharmacological effects have implications for the development of muscle relaxants and other drugs that target neuromuscular function. Understanding the mechanisms of action of zoxazolamine and related compounds can provide insights into the treatment of conditions such as muscle spasms, spasticity, and neuromuscular disorders.
Safety Considerations: As a potent muscle relaxant, zoxazolamine should be used with caution in laboratory settings to avoid accidental overdose or misuse. Proper handling and administration protocols should be followed to ensure the safety of researchers and laboratory animals. Additionally, researchers should be aware of potential interactions with other drugs or compounds that affect neuromuscular function.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
ADHD | 0.5 | 0.5 | |
Allergic Rhinitis (Hay Fever) | 0.4 | 0.4 | |
Allergies | 0.6 | 0.9 | -0.5 |
Allergy to milk products | 1.1 | 0.3 | 2.67 |
Alzheimer's disease | 1.6 | 1.3 | 0.23 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 1 | -2.33 |
Ankylosing spondylitis | 1.4 | 0.6 | 1.33 |
Anorexia Nervosa | 0.5 | -0.5 | |
Antiphospholipid syndrome (APS) | 1 | 0.4 | 1.5 |
Asthma | 0.1 | -0.1 | |
Atherosclerosis | 0.5 | 0.5 | |
Atrial fibrillation | 1 | 0.9 | 0.11 |
Autism | 1.5 | 1.8 | -0.2 |
Barrett esophagus cancer | 0.1 | 0.5 | -4 |
benign prostatic hyperplasia | 0.3 | 0.3 | |
Bipolar Disorder | 1.2 | 0.4 | 2 |
Brain Trauma | 0.1 | -0.1 | |
Carcinoma | 1.7 | 0.5 | 2.4 |
Celiac Disease | 1.1 | 0.9 | 0.22 |
Cerebral Palsy | 0.5 | 0.5 | 0 |
Chronic Fatigue Syndrome | 1.6 | 0.6 | 1.67 |
Chronic Kidney Disease | 0.4 | 0.4 | |
Chronic Lyme | 0.1 | -0.1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.6 | 1.6 | |
Chronic Urticaria (Hives) | 1.3 | 0.1 | 12 |
Coagulation / Micro clot triggering bacteria | 1.3 | 0.9 | 0.44 |
Colorectal Cancer | 2.7 | 2.7 | |
Constipation | 0.4 | 0.4 | |
Coronary artery disease | 0.4 | 0.4 | |
COVID-19 | 2 | 2.9 | -0.45 |
Crohn's Disease | 2.2 | 0.7 | 2.14 |
cystic fibrosis | 0.8 | 0.1 | 7 |
deep vein thrombosis | 0.8 | 0.9 | -0.13 |
Depression | 2.2 | 2.1 | 0.05 |
Dermatomyositis | 0.5 | 0.5 | |
Eczema | 0.3 | 1.5 | -4 |
Endometriosis | 1.4 | 0.4 | 2.5 |
Eosinophilic Esophagitis | 0.1 | 0.1 | |
Epilepsy | 1 | 0.1 | 9 |
Fibromyalgia | 0.2 | -0.2 | |
Functional constipation / chronic idiopathic constipation | 1.4 | 0.2 | 6 |
gallstone disease (gsd) | 0.7 | 0.1 | 6 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.5 | -1.5 |
Generalized anxiety disorder | 1 | 0.1 | 9 |
Glioblastoma | 0.5 | -0.5 | |
Graves' disease | 0.1 | 0.1 | |
Halitosis | 0.2 | 0.5 | -1.5 |
Hashimoto's thyroiditis | 0.1 | 0.5 | -4 |
Hidradenitis Suppurativa | 1 | 1 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.6 | 0.6 | |
hyperglycemia | 0.3 | 0.1 | 2 |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 1.3 | 1 | 0.3 |
Hypoxia | 0.1 | 0.1 | |
IgA nephropathy (IgAN) | 0.1 | -0.1 | |
Inflammatory Bowel Disease | 2.4 | 1.5 | 0.6 |
Insomnia | 0.6 | 0.1 | 5 |
Intelligence | 0.1 | -0.1 | |
Intracranial aneurysms | 0.5 | 0.5 | |
Irritable Bowel Syndrome | 1.3 | 0.1 | 12 |
Liver Cirrhosis | 1.8 | 1.4 | 0.29 |
Long COVID | 1 | 1.9 | -0.9 |
Lung Cancer | 0.3 | 0.4 | -0.33 |
ME/CFS with IBS | 0.5 | 0.1 | 4 |
ME/CFS without IBS | 0.6 | 0.1 | 5 |
Metabolic Syndrome | 2.4 | 1.6 | 0.5 |
Mood Disorders | 3 | 2.1 | 0.43 |
multiple chemical sensitivity [MCS] | 1.5 | 1.5 | |
Multiple Sclerosis | 2.4 | 1.1 | 1.18 |
Multiple system atrophy (MSA) | 0.4 | -0.4 | |
Neuropathy (all types) | 0.5 | 0.3 | 0.67 |
neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.9 | 0.5 | 0.8 |
Obesity | 1.7 | 2.5 | -0.47 |
obsessive-compulsive disorder | 2.3 | 0.2 | 10.5 |
Osteoarthritis | 0.9 | 0.4 | 1.25 |
Osteoporosis | 0.8 | 0.1 | 7 |
pancreatic cancer | 0.5 | 0.5 | |
Parkinson's Disease | 1.5 | 1.3 | 0.15 |
Polycystic ovary syndrome | 0.8 | 0.8 | 0 |
Psoriasis | 1.5 | 0.2 | 6.5 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2 | 0.2 | 9 |
Rosacea | 0.4 | 0.4 | |
Schizophrenia | 0.9 | 0.4 | 1.25 |
scoliosis | 0.8 | -0.8 | |
Sjögren syndrome | 0.9 | 0.1 | 8 |
Sleep Apnea | 0.5 | 0.1 | 4 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 1.2 | |
Stress / posttraumatic stress disorder | 0.8 | 0.1 | 7 |
Systemic Lupus Erythematosus | 1.4 | 0.4 | 2.5 |
Tic Disorder | 0.4 | 0.1 | 3 |
Tourette syndrome | 0.1 | -0.1 | |
Type 1 Diabetes | 1.2 | 0.5 | 1.4 |
Type 2 Diabetes | 2.4 | 1.7 | 0.41 |
Ulcerative colitis | 1.8 | 0.6 | 2 |
Unhealthy Ageing | 1.4 | 1.4 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.